Menu Search
Equities

STAAR Surgical Co

SR3:DUS

STAAR Surgical Co

Actions
  • Price (EUR)29.05
  • Today's Change0.44 / 1.54%
  • Shares traded--
  • 1 Year change-10.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year STAAR Surgical Co's net income fell -46.18% from 39.67m to 21.35m despite revenues that grew 13.37% from 284.39m to 322.42m. An increase in the selling, general and administrative costs as a percentage of sales from 50.49% to 55.88% was a component in the falling net income despite rising revenues.
Gross margin78.73%
Net profit margin6.38%
Operating margin7.53%
Return on assets4.32%
Return on equity5.40%
Return on investment4.92%
More ▼

Cash flow in USDView more

In 2023, STAAR Surgical Co increased its cash reserves by 111.65%, or 96.56m. Cash Flow from Investing totalled 74.35m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 14.59m in cash from operations while cash generated from financing totalled 7.42m.
Cash flow per share0.5597
Price/Cash flow per share52.71
Book value per share8.69
Tangible book value per share8.65
More ▼

Balance sheet in USDView more

STAAR Surgical Co has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 183.04m.
Current ratio5.99
Quick ratio5.38
Total debt/total equity0.0002
Total debt/total capital0.0002
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)31.52
EPS (TTM) vs
TTM 1 year ago		6.42
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.